



PRESS RELEASE

Berlin, 24 November 2016

Clinical Study Shows Bacteria Are Good For Your Skin

In a clinical study, the biotechnology firm Organobalance examined the effectiveness of a lactic acid bacteria extract on the skin and demonstrated significant improvement in participants diagnosed with dry skin. Identified from the company's proprietary collection of yeast and bacterial strains, the bacterium *Lactobacillus brevis DSMZ17250* showed anti-inflammatory properties in the study while simultaneously boosting the skin's colonisation with protective, symbiotic microorganisms. The study is published in journal *Beneficial Microbes*. (<http://www.wageningenacademic.com/doi/abs/10.3920/BM2016.0073>)

Prof. Dr. Christine Lang, microbiologist and Managing Director of Organobalance GmbH, emphasises that "the extract we gained from natural bacteria can be used as a basis for a range of skin care products." During the four-week study period, the research team found that daily treatment with its cell-free lactobacillus extract significantly reduced skin dehydration and, as a result, symptoms such as itching, dry or burning skin. Simultaneously, the skin's microbiota was improved, and there was clear evidence that the growth of several bacterial strains which help protect the skin, such as *Staphylococcus epidermidis*, was stimulated. The Extract is licensed to Organobalance Medical AG (new: Belano Medical AG) for cosmetic applications.

Commissioned by, among others, the food industry and producers of pharmaceuticals, cosmetics, or feed, or for industrial biotechnology, Organobalance relies on its proprietary collection of several thousand lactobacillus strains when researching agents and developing new products. In recent years, the company developed products for the probiotic prevention and treatment of bacterial infections such as tooth decay, gastric ulcers, and skin disorders, as well as agents against odours caused by bacteria, e.g. the smell of sweat. In September, Organobalance was incorporated into the Danish company Novozymes A/S.

About Organobalance:

Organobalance GmbH is a biotechnology research and development company with facilities in Berlin and Flensburg. Founded in 2001, the firm develops and markets products based on probiotic bacteria cultures as well as yeast production strains for use in industrial biotechnology. One of its best known products is Pylopass™, a natural agent against *Helicobacter pylori*, a stomach bacterium. Among the company's German and international customers are clients from the food, cosmetics, feed, agriculture, and pharmaceutical industries. The company owns an extensive collection of yeast and lactobacillus cultures, some of which date back to the 1920s. In addition, Christine Lang, the company's Managing Director, is also a Professor of Microbiology and Molecular Genetics at the TU Berlin and has received several business awards. In September 2016, Organobalance was incorporated into the Danish company Novozymes A/S.



For further information:
ORGANO BALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin, Germany
Fon +49 (0) 30 46307 200
Fax +49 (0) 30 46307 210
www.organobalance.com